Tax Inversions and Price Attacks: Will Wyden Make the Link?
This article was originally published in RPM Report
Executive Summary
Finance Committee Chair Ron Wyden is promising immediate action to stop the trend of biopharma companies acquiring ex-US firms to reincorporate for tax reasons. The prospects for legislation are limited – but will the debate open up a new angle to attack biopharma pricing in the US?